WithdrawnPhase 3NCT02590601

Bromocriptine in the Treatment of Peripartum Cardiomyopathy

Studying Peripartum cardiomyopathy

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Montreal Heart Institute
Principal Investigator
Robert Avram, MD, MBChB
Université de Montréal
Intervention
Bromocriptine(drug)
Eligibility
18 years · FEMALE
Timeline
2017 – 2023

Study locations (1)

Collaborators

Canadian Cardiovascular Society

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02590601 on ClinicalTrials.gov

Other trials for Peripartum cardiomyopathy

Additional recruiting or active studies for the same condition.

See all trials for Peripartum cardiomyopathy →

← Back to all trials